Literature DB >> 26561922

PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?

Feriyl Bhaijee1, Robert A Anders2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26561922     DOI： 10.1001/jamaoncol.2015.3782

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  21 in total

Review 1.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

2.  Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma.

Authors:  Ivan Pourmir; Johanna Noel; Audrey Simonaggio; Stéphane Oudard; Yann-Alexandre Vano
Journal:  World J Urol       Date:  2021-01-02       Impact factor: 4.226

3.  Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.

Authors:  Amber M Bates; Emily A Lanzel; Fang Qian; Taher Abbasi; Shireen Vali; Kim A Brogden
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-05-25

Review 4.  Towards tumor immunodiagnostics.

Authors:  Helen Kourea; Vassiliki Kotoula
Journal:  Ann Transl Med       Date:  2016-07

Review 5.  Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.

Authors:  Eric K Ring; James M Markert; G Yancey Gillespie; Gregory K Friedman
Journal:  Clin Cancer Res       Date:  2016-11-10       Impact factor: 12.531

6.  PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression.

Authors:  Kim A Brogden; Shireen Vali; Taher Abbasi
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

7.  PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.

Authors:  Marius Ilie; Alexander T Falk; Catherine Butori; Emmanuel Chamorey; Christelle Bonnetaud; Elodie Long; Sandra Lassalle; Katia Zahaf; Nicolas Vénissac; Jérôme Mouroux; Charlotte Cohen; Elisabeth Brambilla; Charles Hugo Marquette; Véronique Hofman; Paul Hofman
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

8.  Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.

Authors:  Emily A Lanzel; M Paula Gomez Hernandez; Amber M Bates; Christopher N Treinen; Emily E Starman; Carol L Fischer; Deepak Parashar; Janet M Guthmiller; Georgia K Johnson; Taher Abbasi; Shireen Vali; Kim A Brogden
Journal:  Cancer Immunol Immunother       Date:  2016-09-29       Impact factor: 6.968

9.  Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Authors:  David A Fabrizio; Thomas J George; Richard F Dunne; Garrett Frampton; James Sun; Kyle Gowen; Mark Kennedy; Joel Greenbowe; Alexa B Schrock; Aram F Hezel; Jeffrey S Ross; Phillip J Stephens; Siraj M Ali; Vincent A Miller; Marwan Fakih; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2018-08

Review 10.  TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.

Authors:  Khalil Choucair; Susan Morand; Laura Stanbery; Gerald Edelman; Lance Dworkin; John Nemunaitis
Journal:  Cancer Gene Ther       Date:  2020-04-28       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.